Suppr超能文献

[膀胱可切除性肉瘤样癌患者的临床病理特征及影响预后因素分析]

[Analysis of Clinicopathological Characteristics and Factors Affecting the Prognosis of Patients With Resectable Sarcomatoid Carcinoma of the Bladder].

作者信息

Huang Shiwang, Jia Kaipeng, Shen Chong, Chen Huitong, Zhang Zhe, Wu Zhouliang, Qie Yunkai, Guo Jianing, Hu Hailong

机构信息

( 300211) Department of Urology, Second Hospital of Tianjin Medical University, Tianjin 300211, China.

( 300211) Tianjin Institute of Urology, Tianjin 300211, China.

出版信息

Sichuan Da Xue Xue Bao Yi Xue Ban. 2024 Sep 20;55(5):1085-1091. doi: 10.12182/20240960102.

Abstract

OBJECTIVE

To investigate the clinicopathological characteristics and the factors affecting the prognosis of patients with resectable sarcomatoid carcinoma of the bladder (SCB).

METHODS

A retrospective analysis was conducted with the clinical data of patients with resectable SCB treated at the Second Hospital of Tianjin Medical University between September 2008 and December 2023. The patients were divided into two groups, a bladder-preserving surgery (BPS) group and a radical cystectomy (RC) group, according to the specific surgical approach used for each patient. Kaplan-Meier survival curves were used to evaluate overall survival (OS) in both groups, and Cox regression models were employed to identify risk factors affecting survival.

RESULTS

A total of 77 patients with resectable SCB were included. Among them, 35 patients (45.5%) underwent BPS, while 42 patients (54.5%) underwent RC. Ki-67 expression≥30% was observed in 91.7% of the patients. A total of 92.2% of the patients was tested positive for cytokeratin (CK) and 98.1% for vimentin. In addition, 62.5% and 37.5% of patients had the human epidermal growth factor receptor 2 (Her-2) scores of 0 and 1+, respectively. The median follow-up time was 23.2 months (ranging from 0.4 to 164.7 months). The 1-year, 3-year, and 5-year survival rates for the BPS group and the RC group were as follows, 76.2% vs. 84.9%, 46.7% vs. 61.1%, and 35.6% vs. 43.2%, respectively. Multivariate Cox regression analysis revealed that in the RC group, age≥75 years old (hazard ratio [HR]=3.836, 95% confidence interval [CI]: 1.168-12.595, =0.027), tumor multiplicity (HR=3.439, 95% CI: 1.235-9.574, =0.018), and lack of adjuvant therapy (HR=3.164, 95% CI: 1.015-9.862, =0.047) were independent risk factors affecting survival. In the BPS group, female sex was identified as an independent risk factor for survival (HR=3.601, 95% CI: 1.200-10.804, =0.022).

CONCLUSION

Ki-67, CK, and vimentin are significantly overexpressed in SCB patients, while Her-2 is either unexpressed or expressed at low levels. In the RC group, tumor multiplicity, age ≥75 years, and lack of postoperative adjuvant therapy are independent risk factors for overall survival. Female sex is an independent risk factor affecting prognosis in the BPS group.

摘要

目的

探讨可切除性膀胱肉瘤样癌(SCB)患者的临床病理特征及影响预后的因素。

方法

回顾性分析2008年9月至2023年12月在天津医科大学第二医院接受治疗的可切除性SCB患者的临床资料。根据每位患者所采用的具体手术方式,将患者分为两组,即保膀胱手术(BPS)组和根治性膀胱切除术(RC)组。采用Kaplan-Meier生存曲线评估两组患者的总生存期(OS),并使用Cox回归模型确定影响生存的危险因素。

结果

共纳入77例可切除性SCB患者。其中,35例(45.5%)接受了BPS,42例(54.5%)接受了RC。91.7%的患者Ki-67表达≥30%。92.2%的患者细胞角蛋白(CK)检测呈阳性,98.1%的患者波形蛋白检测呈阳性。此外,62.5%和37.5%的患者人表皮生长因子受体2(Her-2)评分分别为0和1+。中位随访时间为23.2个月(范围为0.4至164.7个月)。BPS组和RC组的1年、3年和5年生存率如下:76.2%对84.9%、46.7%对61.1%、35.6%对43.2%。多因素Cox回归分析显示,在RC组中,年龄≥75岁(风险比[HR]=3.836,95%置信区间[CI]:1.168-12.595,P=0.027)、肿瘤多发(HR=3.439,95%CI:1.235-9.574,P=0.018)以及未接受辅助治疗(HR=3.164,95%CI:1.015-9.862,P=0.047)是影响生存的独立危险因素。在BPS组中,女性被确定为生存的独立危险因素(HR=3.601,95%CI:1.200-10.804,P=0.022)。

结论

Ki-67、CK和波形蛋白在SCB患者中显著过表达,而Her-2要么未表达,要么低表达。在RC组中,肿瘤多发、年龄≥75岁以及术后未接受辅助治疗是总生存期的独立危险因素。女性是BPS组影响预后的独立危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1140/11536235/d869d2faa8f0/scdxxbyxb-55-5-1085-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验